TABLE 1

Randomised controlled trial data on the use of medical therapies in patients with chronic thromboembolic pulmonary hypertension

	CHEST-1 [68]	*Suntharalingam et al.* [**69]	MERIT-1 [70]	BENEFiT [71]
Patients n	261	19	80	157
Active treatment	Riociguat	Sildenafil	Macitentan	Bosentan
Control	Placebo	Placebo	Placebo	Placebo
Treatment duration weeks	16	12	24	16
Population n (%)
Inoperable	189 (72.4)	10 (52.6)	80 (100)	96 (70.1)
Persistent/recurrent PH post-pulmonary endarterectomy	72 (27.6)	9 (47.4)	0	41 (29.9)
Use of PAH therapy at baseline n (%)
No	261 (100.0)	19 (100.0)	31 (38.8)	157 (100.0)
Yes	0	0	49 (61.3)	0
Primary end-point	Change in 6MWD from baseline to week 16	Change in 6MWD from baseline to week 12	PVR at week 16 as a percentage of baseline	Change in PVR and 6MWD from baseline to week 16 (co-primary end-points)
Treatment effect on 6MWD	+46 (25–67) m, p<0.001^#	+18 (−24–59) m, p=ns	+34 (3–65) m, p<0.05^#	+2 (−23–27) m, p=ns
Treatment effect on PVR	−246 (−303– −190) dyn·s·cm⁻⁵, p<0.001^#	−197 (−389– −6) dyn·s·cm⁻⁵, p<0.05	0.84^¶ (0.70–0.99), p<0.05⁺	−24%^§ (−32– −16%), p<0.0001⁺
Treatment effect on mPAP	−5 (−7–−3) mmHg, p<0.001^#	−6 (−12–0) mmHg, p=ns	−2 (−6–2) mmHg, p=ns^#	−3 (−5–0) mmHg, p=ns

Data are presented as n, n (%) or mean difference (95% CI), with p-value, between active and control groups, unless otherwise stated. PH: pulmonary hypertension; PAH: pulmonary arterial hypertension; 6MWD: 6-min walk distance; PVR: pulmonary vascular resistance; mPAP: mean pulmonary arterial pressure; ns: nonsignificant. ^#: treatment effect is the least-squares mean difference; ^¶: corresponds to a 16% reduction, PVR decreased by 206 dyn·s·cm⁻⁵ in the macitentan group and 86 dyn·s·cm⁻⁵ in the placebo group; ⁺: treatment effect is the ratio of geometric means; ^§: PVR decreased by 146 dyn·s·cm⁻⁵ in the bosentan group and increased by 30 dyn·s·cm⁻⁵ in the placebo group.